Krystal Biotech seeks US FDA approval for B-VEC to treat patients with dystrophic epidermolysis bullosa
Krystal Biotech, Inc., the leader in redosable gene therapy, announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB).
B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by providing the patient
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!